Fibroblast Growth Factor 2

PreclinicalSmall molecule

Fibroblast Growth Factor 2 is one of 2 small molecule programs targeting Tympanic Membrane Perforation. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Tympanic Membrane PerforationActive, not recruiting

Tympanic Membrane PerforationPreclinical

Active, not recruiting

Competition

Competitive Landscape

1 competitor in Tympanic Membrane Perforation

#DrugCompanyPhaseTrials

Fibroblast Growth Factor 2

DD. Bradley Welling, MD, PhD

Preclinical

1 2

Saline Control

DD. Bradley Welling, MD, PhD

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

PreclinicalActive, not recruiting

Tympanic Membrane Perforation

NCT06448039

Clinical

Trials by Indication[1]

Tympanic Membrane Perforation1 trial

In-office Repair of Chronic Tympanic Membrane Perforations

Active, not recruiting·DD. Bradley Welling, MD, PhD·Preclinical·NCT06448039·20 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Fibroblast Growth Factor 2. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Fibroblast Growth Factor 2 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Fibroblast Growth Factor 2. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — D. Bradley Welling, MD, PhD company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: DD. Bradley Welling, MD, PhD

Fibroblast Growth Factor 2

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Trials by Indication[1]

Tympanic Membrane Perforation1 trial

References

Drug Info

Quick Facts

Related News